Ori Biotech
We're on a mission to enable widespread patient access to a new generation of lifesaving Cell and Gene Therapies.
Ori Biotech
We're on a mission to enable widespread patient access to a new generation of lifesaving Cell and Gene Therapies.
TL;DR
What they do: Develop the IRO® closed, automated full‑stack manufacturing platform for cell and gene therapies
Founded: 2015
Headcount (approx.): 90 employees
Known funding: Series A $30M (2020), Series B >$100M (2022); disclosed total funding ≈ $139.1M
Company Overview
Problem Domain
Cell and gene therapy (CGT) manufacturing — process automation, scale-up, and translation from R&D to GMP/commercial production.
Founded
2015
Industry
Biotechnology
Funding Track Record
9400000.00
30000000.00
Series A brought total funding to date to $41M per company disclosure
100000000.00
Described as over $100M and oversubscribed; new investors included Puhua Capital and Chimera Abu Dhabi
Investor Signal
“Institutional life‑science investors including Amadeus Capital Partners, Delin Ventures, Kindred Capital, Northpond Ventures, Octopus Ventures and Novalis LifeSciences”